Dr. Cudkowicz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Mass General Hospital
15 Parkman Street ACC 7
Boston, MA 02114Phone+1 617-726-0813Fax+1 617-726-4803- Is this information wrong?
Summary
- Dr. Merit Cudkowicz is a neurologist in Boston, MA and is affiliated with Massachusetts General Hospital. She received her medical degree from Harvard Medical School and has been in practice 35 years. She specializes in the care of people with ALS and neurotherapeutics. She co-founded and co-directed the Northeast ALS Consorrtium, a group now of over 150 centers who work collaboratively to accelerate the development of treatments for people with ALS. She has expertise in clinical trial design and conduct. She designed and leads the first platform trial in ALS, the Healey ALS Platform Trial. She is also the Principal Investigator for the Clinical Coordination Center for the NINDS supported NeuroNEXT phase II clinical trial network.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1991 - 1994
Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1990 - 1991
Harvard Medical SchoolClass of 1990
Certifications & Licensure
CT State Medical License Current
FL State Medical License 2022 - 2026
MA State Medical License 1994 - 2025
ME State Medical License 2021 - 2025
NH State Medical License 2021 - 2025
RI State Medical License 2021 - 2024
VT State Medical License 2021 - 2024- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Ray Adams Lectureship American Neurological Association, 2019
- America's Top Doctors Castle Connolly, 2012-2019
- Boston Magazine Castle Connolly, 2012-2013
Clinical Trials
- Determinants of Disease Severity in Amyotrophic Lateral Sclerosis Start of enrollment: 1998 Mar 01
- A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS Start of enrollment: 2005 Oct 01
- Pilot Study of Minocycline in Huntington's Disease Start of enrollment: 2006 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes.Stacy R Lindborg, Namita A Goyal, Jonathan Katz, Matthew Burford, Jenny Li, Haggai Kaspi, Natalie Abramov, Bruno Boulanger, James D Berry, Katharine Nicholson, Tahseen...> ;Muscle & Nerve. 2024 Apr 9
- Artificial intelligence in neurology: opportunities, challenges, and policy implications.Sebastian Voigtlaender, Johannes Pawelczyk, Mario Geiger, Eugene J Vaios, Philipp Karschnia, Merit Cudkowicz, Jorg Dietrich, Ira R J Hebold Haraldsen, Valery Feigin, M...> ;Journal of Neurology. 2024 May 1
- 1 citationsIdentification of gene fusions associated with amyotrophic lateral sclerosis.Raghav, Y., Dilliott, A., Petrozziello, T., Kim, S., Berry, J., , Fraenkel, E., Farhan, S., Sadri-Vakili, G., Cudkowicz, M., Vakili, K.> ;Muscle & Nerve. 2024 Apr 1
- Join now to see all
Lectures
- 65th AAN Annual MeetingAmerican Academy of Neurology (AAN), San Diego, California - 3/16/2013
Other
- Disease modifying treatment of amyotrophic lateral sclerosisCudkowicz ME, Galvez-Jimenez N, Choudry RB
http://www.uptodate.com/contents/disease-modifying-treatment-of-amyotrophic-lateral-sclerosis
UpToDate, Wolters Kluwer Health - 2012-12-03
Press Mentions
Calico Life Sciences Announces First Participant Dosed in Phase 1b Clinical Study Evaluating ABBV-CLS-7262 for the Treatment of Vanishing White Matter DiseaseApril 26th, 2023- Prilenia Shares Preliminary Topline Results from Phase 3 PROOF-HD Clinical Trial in Huntington's Disease and Data from Phase 2 HEALEY ALS Platform Trial of Pridopidine at the 75th American Academy of Neurology (AAN) Annual MeetingApril 25th, 2023
- Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS StudyFebruary 23rd, 2023
- Join now to see all
Grant Support
- Clinical Coordinating Center Network Of Excellence In Neuroscience Clinical TrialNational Institute Of Neurological Disorders And Stroke2011
- Phase II/III Study Of Arimoclomol In The Treatment Of SOD1 Positive Familial?.Food And Drug Administration2011
- Clinical Trial Of Ceftriaxone In Subjects With ALSNational Institute Of Neurological Disorders And Stroke2010–2011
- Multi-Center Validation Of Biomarkers For Motor Neuron DiseaseNational Institute Of Neurological Disorders And Stroke2010
- Multi-Center Validation Of Biomarkers For Motor Neuron DiseaseNational Institute Of Neurological Disorders And Stroke2009–2010
- Generation And Characterization Of Amyotrophic Lateral Sclerosis IPS CellsNational Institute Of Neurological Disorders And Stroke2009–2010
- Coenzyme Q10 In Huntington'S DiseaseNational Institute Of Neurological Disorders And Stroke2008–2010
- Clinical Trial Of Ceftriaxone In ALSNational Institute Of Neurological Disorders And Stroke2006–2009
- Clinical Trial: Open-Label Arimoclomol Extension ProtocolNational Center For Research Resources2008
- Phase II/III Study Of Arimoclomol In The Treatment Of SOD1 Positive Familial?.Food And Drug Administration2008
- Open-Label Arimoclomol Extension ProtocolNational Center For Research Resources2007
- Identification Of Diagnostic Biomarkers And Therapeutic Agents For ALSNational Center For Research Resources2007
- Safety And Pharmacokinetics Study Of Arimoclomol In ALSNational Center For Research Resources2006–2007
- Multi-Dose Placebo-Controlled Phase I Study Of AEOL 10150 In Patients With ALSNational Center For Research Resources2006–2007
- Coenzyme Q10 In Huntington'S DiseaseNational Institute Of Neurological Disorders And Stroke2005–2007
- Double Blind Study Of Minocycline In HDFood And Drug Administration2005–2007
- Safety Study Of Aeol10150 In Patients With Amyotrophic Lateral SclerosisNational Center For Research Resources2006
- Safety And Dose Escalating Study Of Napb In ALSNational Center For Research Resources2006
- Determ Of Biological Mrkrs In Cerebrospinal Fld Subj W/Amyotrophic Ltral ScleroNational Center For Research Resources2005
- A Clinical Trial Of Coenzyme Q10 In Patients With Amyotrophic Lateral SclerosisNational Center For Research Resources2005
- Metabolomic Signatures In ALSNational Institute Of Environmental Health Sciences2004–2005
- Pilot Safety And Tolerability Study Of COQ10 In HD And In NormalNational Center For Research Resources2004–2005
- Histamine Dihydrochloride In ALSNational Center For Research Resources2004–2005
- Clinical Trial Of Celebrex In Subjects With Amyotrophic Lateral Sclerosis (ALS)National Center For Research Resources2004–2005
- Clinical Trial Of Ceftriaxone In ALSNational Institute Of Neurological Disorders And Stroke2004
- Clinical Trial Of Coenzyme Q10 In Patients With ALSNational Center For Research Resources2004
- Clinical Trial Of Topiramate In ALSNational Institute Of Neurological Disorders And Stroke2000–2003
- Topiramate Clinical Trial In Amyotrophic Lateral SclerosNational Center For Research Resources2000–2002
- Rmethubdnf Intrathecal Infusion In ALSNational Center For Research Resources2000–2002
- Coenzyme Q10 And Remacemide--Evaluation In Huntington'S DiseaseNational Center For Research Resources1998–2002
- Risk Factors And Therapeutic Strategies In ALSNational Institute Of Neurological Disorders And Stroke1996–2000
- Biological Markers In CSF In Subjects With Amyotrophic Lateral SclerosisNational Center For Research Resources1998–1999
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
